Metabolic Syndrome Consequent to Endocrine Disorders. Группа авторов

2014;9:e90602.

9Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; Executive summary of the third report of the national cholesterol education programme (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.

10Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Shepard MC, Bates AS, Stewart PM: Mortality in patients with pituitary disease. Endocrine Reviews 2010;31:301–342.

      11Olsson DS, Nilsson AG, Brygelsson IL, Trimpou P, Johansson G, Andersson E: Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Sweedish Nationwide Study. J Clin Endocrinol Metab 2015;100:2651–2658.

12Tomilson JW, Holden N, Hills RK, et al: Association between premature mortality and hypopituitarism. Lancet 2001;357:425–431.

13Gaillard RC, Matisson AF, Åkerblad AC, Bengtsson BA, Cara J, Feldt-Rasmunssen U, Kotlowska-Häggström M, Monson JP, Saller B, Wilton P, Abs R: Overall and cause-specific mortality in GH-deficient adults on GH replacement. Overall and cause-specific mortality in GH-deficient patients on GH replacement. Eur J Endocrinol 2012;166:1069–1077.

14Svensson J, Bengtsson BÅ, Rosén T, Odén A, Johansson G: Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004;89:3306–3312.

15Verhelst J, Kendall-Taylor P, Erfurt EM, Price DA, Geffner M, Koltowska-Häggström M, Jönsson PJ, Wilton P, Abs R: Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngeoma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database) J Clin Endocrinol Metab 2005;90:4636–4643.

16Weber M, Biller BMK, Tønnes Pedersen B, Pornara E, Christiansen JS, Höybye C: The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult non-diabetic patients with GH deficiency: real-life data from the Nordinet® international outcome study. Clin Endocrinol 2017;86:192–198.

17O’Reilly MW, Reulen RC, Gupta S, Thompson CA, Dineen R, Goulden EL, Bugg G, Pearce H, Toogood AA, Gittoes NJ, Mitchell R, Thompson CJ, Ayuk J: ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centers. Clin Endocrinol 2016;85:748–756.

18Filipson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johansson G: The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91:3954–3961.

19Hammarstand C, Ragnarsson O, Hallén T, Andesson E, Skoglund T, Nilsson AG, Johansson G, Olsson DS: Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol 2017;177:251–256.

20Filipsson H, Johansson G: GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 2008;161:S85–S95.

      21Koulouri O, Auldin M, Agarwal R, Keiffer V, Robertson C, Falconer Smith J, Levy M, Howlett T: Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011;6:744–749.

22Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, Peper M, Lubrich B, Hug MJ, Nauck M, Olschewski M, Beuchlein F, Reincke M: Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxin (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007;92:4115–4122.

23Mah PM, Webster J, Jonsson P, Feldt-Rasmunssen U, Koltowska-Häggström M, Ross RJ: Estrogen replacement in women in fertile years with hypopituitarism. J Clin Endocrinol Metab 2005;90:5964–5969.

      24Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK: Oral estrogen antagonizes the metabolic action of growth hormone in growth hormone deficient women. Am J Physiol Endocrinol Metab 2001;281:E1191–E1196.

25Birzniece V, Ho K: Sex steroids and the GH axis: Implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metab 2017;31:1–11.

26Abs R, Mattsson AF, Bengtsson BA, Feldt-Rasmunssen U, Goth MI, Koltowska-Häggström M, Monson JP, Verhelst J, Wilton P: Isolated growth hormone (GH) deficiency in adult patients: baseline characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS data base. Growth Horm IGF Res 2005;15:349–359.

27Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN: Coronary risk in growth hormone deficient adults; increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol 2001;55:209–216.

28Van der Klaauw AA, Romijn JA, Biermasz NR, et al: Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006;155:702–708.

29Göthertströrm G, Svensson J, Koranyi J, et al: A prospective study of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab 2001;86:4657–4665.

      30Colson A, Brooke AM, Walker D, et al: Growth hormone deficiency and replacement in patients with treated Cushing’s disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res 2006;66:257–267.

31Elbornsson M, Götherström G, Bosaus I, Bengtsson BA, Johannsson G, Svensson J: Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013;168:745–753.

32Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P: Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004;89:2192–2199.

33SpielhagenC, Schwahn C. Möller K, et al: The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Hormone IGF Res 2011;21:1–10.